Roadshow Project Registration

Displaying 1 - 2 of 46
Contact Name
Eugene Dinescu
Contact Email
eugene@vasocuretherapuetics.com
Contact Phone Number
(732) 690-0920
Supplemental information (You may upload your business plan here.)
Your comment (optional)
Contact Job Title
CEO
Company Name
Vasocure
Where is your company registered? (City, State, Country)
New York, NY, USA
When was the company founded (year only)?
2018
Please choose the best keyword to describe your company/project?
Small Molecule Pharmaceuticals
If you choose "Other" on the previous question, please enter your answer here:
Please choose the best choice from below to describe your company/project
Phase I
From which SAPA chapter did you learn about this roadshow event? (Please specify the referrer's name)
Other
If you choose "Other" on the previous question, please enter your answer here:
Mary Howard
Founder(s) and Management Team
MANAGEMENT
Eugene Dinescu, BA Biochemistry, Columbia U., Columbia Executive Management Program, Former Director Flatlands Medical Associates, Founder, CEO
Anna Babinka, PhD Microbiology, Professor Department of Medicine SUNY Downstate, Founder, CSO Elizabeth Kornecki, PhD Cell Biology, Former Professor Emeritus Department of Medicine, Founder, VP of R&D
Yigal Ehrlich, PhD Cell Biology, Former Professor Emeritus Department of Medicine CUNY, Founder, VP of R&D
BOARD
Moro Salifu, MD, MBA, MPH, Nephrologist, Chairman of SUNY Downstate Medical Center, Founder Aditya Mattoo, MD, MBA, Former Professor of Medicine at NYU, Nephrologist, Founder
What is your core business?
Vasocure is a novel platform biotherapeutics company with over 62 drug candidates in nephrologyy, cardiology, and oncology. Vasocure was founded after 25 years of pioneering academic research including hundreds of publications and the discovery of the F11R Receptor, analogous to JAM-A. We are currently in the process of filing an IND for Pedifin, the world’s first drug candidate shown to prevent and reverse neointimal disease in animal models.
What is the value and innovation of your core business?
Company owns and is developing 62 candidates including oral mimetics in nephrology, cardiology, and oncology.
• Focusing on neointimal disease (in the renal space due to FDA fast track (high priority indication)
Ø Pedifin is a first-in-class, 1st generation, IV investigational drug that is a highly selective competitive inhibitor of F11R, currently seeking IND for FIH (First in human) Phase 1.
Ø F11R (F11 Receptor) is over-expressed in neointimal disease and atherosclerotic plaques.
Ø By blocking F11R, Pedifin can effectively inhibit narrowing of the lumen, which means better blood flows, better dialysis and better survival for patients.
Ø Pedifin, has been shown in animal models to be highly effective at preventing and reversing neointimal hyperplasia as well as atherosclerotic plaque formation.
UNMET NEED
• 15% of the US population (49 million people) is affected by chronic kidney disease (CKD) with a CAGR of 5.7%.
What is your target market and what is the potential market size?
UNMET NEED
• 15% of the US population (49 million people) is affected by chronic kidney disease (CKD) with a CAGR of 5.7%.
• 45% of CKD patients have diabetes or self-reported cardiovascular disease.
• 550,000 Americans suffer from kidney failure and are on hemodialysis through a
vascular access.
• 100% of dialysis patients will require surgery
What are your risks and who are your competitors?
COMPETITION
• The only treatment is surgical, Pedifin is the first pharmacologic treatment.
What is your project’s IP position?
INTELLECTUAL PROPERTY
Portfolio of Approved Patents: 3 Patent Applications filed: 4
Additional disclosed on slide deck
What is your development plan for the next 3-5 years?
Complete Phase 1 and 2 Clinical Trials for pedifin and begin Phase 1 for at least two more candidates.
How much fund have you raised so far? From which investor(s)?
Funding to date: $5M Grants, $500K Founders
What investment amount are you seeking?
Financing sought: $5.5M ($4.5M R&D, $1M Salaries and Legal)
Description of the Project
MILESTONES
• Incorporated (Q4 2018)
• START-UP NY company, awarded 10 years tax-free operations (Q1 2019)
• Accepted in SUNY Downstate Incubator Labs (Q1 2020)
• State-of-the-art facilities in NYC and Lodz, Poland (Q1 2020)
• Successful completion of 95% preclinical studies with IND filing (Q4 2021)
• Estimated dose studies completed, 25mg/kg administered 1X/week
• Multiple IP filings (Q3-Q4 2021)
If you choose "Other" on the previous question, please enter your answer here:
Company website
www.vasocuretherapeutics.com
Entry ID
160
Sequence Number
2